JERSEY CITY, N.J., May 24, 2018 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovativetherapies for difficult-to-treat and often life-threatening infections, today announced three poster presentations at American Society for Microbiology (ASM) Microbe 2018, June 7-11, 2018, in Atlanta.
Title: Morphological Effect of SCY-078 and Caspofungin on Different Echinocandin-Resistant Candida SpeciesPoster Presentation #: 497Presenter: Mahmoud Ghannoum, PhD
Title: In Vitro Activity of SCY-078 in Combination with Isavuconazole Or Amphotericin B against Medically Important MouldsPoster Presentation #: 498Presenter: Vidmantis Petraitis, PhD
Title: Does Sabouraud Dextrose Broth, Compared to RPMI, Differentiate Susceptibility between Resistant and Susceptible C. glabrata and C. albicans Isolates to SCY-078, A Novel ?-D-Glucan Synthase Inhibitor and Caspofungin?Poster Presentation #: 506Presenter: Mahmoud Ghannoum, PhD
The ASM Microbe 2018 posters will be presented at the session "Antifungal Agents and Resistance: Agents to Treat Fungal Infections" on Friday, June 8, from 11:00-13:00 ET, and will be available on the SCYNEXIS website following the event.
About SCYNEXISSCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by developing innovative therapies. The SCYNEXIS team has extensive experience in the life sciences industry, discovering and developing more than 30 innovative medicines over a broad range of therapeutic areas. The Company's lead product candidate, SCY-078, is a novel IV/oral antifungal agent in Phase 2 clinical and pre-clinical development for the treatment of multiple serious and life-threatening invasive fungal infections caused by Candida and Aspergillus species. For more information, visit www.scynexis.com.
Investor RelationsSusan KimArgot PartnersTel: email@example.com
Media RelationsGeorge E. MacDougallMacDougall Biomedical CommunicationsTel: firstname.lastname@example.org
View original content:http://www.prnewswire.com/news-releases/scynexis-to-present-scy-078-data-at-asm-microbe-2018-300652073.html
SOURCE SCYNEXIS, Inc.
Subscribe to our Free Newsletters!
True vertigo is a severe form of dizziness that is a movement hallucination. Try out some of these ...
Oxidative stress is a form of injury to body tissues due to increase in free radicals. If the ...
Graviola's health benefits range from curing headaches to fighting cancer. Read on to know more ...View All